Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : MultiCell Technologies, Inc. -- Ignore unavailable to you. Want to Upgrade?

To: Shawn Donahue who wrote (49)	5/10/2005 3:55:11 PM
From: EACarl	Respond to of 237

Shawn, Sorry for the delayed reply, but I haven't signed on here lately. As for your question about my shareholder status, I sold out about a year ago in the mid .30's. It's been lower and it's been higher, but unfortunately the dilution is never ending here, and I don't see enough evidence of sales to warrant buying back. I'm certainly not hanging around for many years away stem-cell related potential. I would consider changing my mind if I did see some indication of significantly improving cell sales. On the Xenotech issue, since the $525,000 minimum quarterly payment is not yet past due, I don't think an announcement would be required unless Xenotech flat out told them they did not intend to send it, and why would they? Why not keep your options open if you are Parkinson. I do think the Language chosen in the recent "Q" is a very strong indicator of how this may play out though......... "It is the Company's belief that the collectibility of such minimum amount is not reasonably assured." You should also consider the possibility that the two companies may continue to work together but under renegotiated terms. i.e no minimums, which still would be a very negative event since the money behind that contract is all MUCL had going for it. RE "Whatever number of pharmaceutical companies are evaluating MCT's immortalized hepatocytes, obviously, there are at least that many paying customers." No, that was not my understanding. At least there is a very significantly reduced cost and I doubt a 90 day evaluation turned into a 365+ day evaluation which means these companies decided making the change was not in their best interest. RE "2 of the top pharmas in the world, Pfizer and a major Japanese company, have paid well, IMHO for the privilege of using the cells." Eisai (the Japanese company you mention) is the ONLY signed full paying customer to date - this has been confirmed by the company recently. Pfizer pays a mere $1000 renewal license. RE "the accountants removed the going concern verbiage from the MUCL Report!" This was simply a function of the recent $4 million financing which came at a huge loss of your ownership stake. The dilutive shares were issued at a net cost significantly below the 52 week low. With any more "good" news like that, You'll be diluted into oblivion. I'm assuming you are aware that Cataldo is trying to get another $10 million dollars - which will dilute the company about another 50%. Also insiders want to award themsleves another 20 million shares worth of options at the annual meeting. The negatives are quite real, but the positives are always years away possibilities. Regards, Eric.